Patients with severe eosinophilic asthma who used depemokimab administered every 6 months experienced a 54% reduction in exacerbations over 52 weeks, according to a study presented at the European ...

Depemokimab is a monoclonal antibody targeting interleukin-5 (IL-5), which plays a crucial role in type 2 inflammation, commonly found in patients with difficult-to-treat asthma and up to 80% of ...

Depemokimab is an ultra-long-acting biologic therapy with enhanced binding affinity for interleukin-5 that may enable effective 6-month dosing intervals. In these phase 3A, randomized, placebo ...

Depemokimab targets interleukin-5 (IL-5), a cytokine involved in type 2 inflammation, which is a common underlying factor in several diseases including asthma and CRSwNP.

Depemokimab reduces exacerbations regardless of baseline asthma control, suggesting uncontrolled symptoms are not necessary for response. Depemokimab reduces exacerbations regardless of baseline ...

SAN DIEGO — Patients with asthma who used depemokimab tolerated treatment well while experiencing reductions in rates of clinically significant exacerbations, according to a poster abstract ...

GSK’s blockbuster hopes for depemokimab remain on track after the investigational long-acting asthma treatment has also been shown to reduce nasal polyps in a pair of phase 3 trials.. The ANCHOR ...

Depemokimab is an ultra-long acting biologic with high binding affinity for interleukin-5. This extended half-life allows for twice-yearly (every 6 months) subcutaneous administration.

However, depemokimab was less successful on other secondary endpoints analyzed individually in the trials, which assessed quality of life, asthma control and how much air a patient can exhale.

Depemokimab Reduces Severe Asthma Exacerbations by Over 50%. Jackson presented promising findings from a pair of phase 3 trials, SWIFT-1 and SWIFT-2, ...

Depemokimab-treated patients with uncontrolled asthma symptoms (ACQ ≥1.5) at baseline were shown to have clinically meaningful improvement at Week 52, with 69% classed as responders based on ...